Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Operating Expenses (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Operating Expenses for 15 consecutive years, with $11.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 7.11% to $11.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $50.5 million, a 4.41% decrease, with the full-year FY2025 number at $53.7 million, up 5.95% from a year prior.
  • Operating Expenses was $11.6 million for Q4 2025 at Aytu Biopharma, up from $10.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $66.1 million in Q1 2022 to a low of $2.9 million in Q1 2021.
  • A 5-year average of $20.6 million and a median of $16.0 million in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: plummeted 77.61% in 2021, then skyrocketed 2179.55% in 2022.
  • Aytu Biopharma's Operating Expenses stood at $23.6 million in 2021, then rose by 2.09% to $24.1 million in 2022, then crashed by 52.43% to $11.5 million in 2023, then rose by 8.94% to $12.5 million in 2024, then fell by 7.11% to $11.6 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Operating Expenses are $11.6 million (Q4 2025), $10.7 million (Q3 2025), and $17.9 million (Q2 2025).